Pharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma.

2.50
Hdl Handle:
http://hdl.handle.net/10541/108054
Title:
Pharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma.
Authors:
Wilkinson, Peter M; O'Neill, Paul A; Thatcher, Nick; Lucas, S B
Abstract:
Cyclophosphamide (CP) was administered to eight patients with metastatic bronchial carcinoma in escalating doses of 1.5, 2.5, and 3.5 g/m2 at intervals of 3 weeks. The proportion of the administered dose converted into alkylating metabolites was similar for each dose and there was no evidence to suggest that the enzyme system responsible for activating CP was saturated even with the highest dose. Considerable between-patient variation in drug metabolism was observed, but within each patient the fraction metabolised remained constant.
Affiliation:
Department of Clinical Pharmacology, Christie Hospital and Holt Radium Institute, M20 9BX Manchester, England.
Citation:
Pharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma. 1983, 11 (3):196-9 Cancer Chemother. Pharmacol.
Journal:
Cancer Chemotherapy and Pharmacology
Issue Date:
1983
URI:
http://hdl.handle.net/10541/108054
DOI:
10.1007/BF00254204
PubMed ID:
6640827
Type:
Article
Language:
en
ISSN:
0344-5704
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorWilkinson, Peter Men
dc.contributor.authorO'Neill, Paul Aen
dc.contributor.authorThatcher, Nicken
dc.contributor.authorLucas, S Ben
dc.date.accessioned2010-07-21T11:45:08Z-
dc.date.available2010-07-21T11:45:08Z-
dc.date.issued1983-
dc.identifier.citationPharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma. 1983, 11 (3):196-9 Cancer Chemother. Pharmacol.en
dc.identifier.issn0344-5704-
dc.identifier.pmid6640827-
dc.identifier.doi10.1007/BF00254204-
dc.identifier.urihttp://hdl.handle.net/10541/108054-
dc.description.abstractCyclophosphamide (CP) was administered to eight patients with metastatic bronchial carcinoma in escalating doses of 1.5, 2.5, and 3.5 g/m2 at intervals of 3 weeks. The proportion of the administered dose converted into alkylating metabolites was similar for each dose and there was no evidence to suggest that the enzyme system responsible for activating CP was saturated even with the highest dose. Considerable between-patient variation in drug metabolism was observed, but within each patient the fraction metabolised remained constant.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAdult-
dc.subject.meshAlkylation-
dc.subject.meshCarcinoma, Bronchogenic-
dc.subject.meshCyclophosphamide-
dc.subject.meshDose-Response Relationship, Drug-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshKinetics-
dc.subject.meshLeukocyte Count-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNeutrophils-
dc.titlePharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Pharmacology, Christie Hospital and Holt Radium Institute, M20 9BX Manchester, England.en
dc.identifier.journalCancer Chemotherapy and Pharmacologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.